References
- George JN. How I treat patients with thrombotic thrombocytopenic purpura. Blood. 2010;116(20):4060–9. doi: 10.1182/blood-2010-07-271445
- Amorosi E, Ultmann J. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45(2):139–59. doi: 10.1097/00005792-196603000-00003
- Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group. N Engl J Med. 1991;325(6):393–7. doi: 10.1056/NEJM199108083250604
- Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500–11; quiz 662. doi: 10.1182/blood-2009-09-243790
- Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010;237(1):264–83. doi: 10.1111/j.1600-065X.2010.00945.x
- Provan D, Newland AC, Amadori S, Stasi R. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;143(2):294; author reply 5. doi: 10.1111/j.1365-2141.2008.07326.x
- Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451–61. doi: 10.1111/j.1365-2141.2006.06448.x
- Chemnitz JM, Uener J, Hallek M, Scheid C. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol. 2010;89(10):1029–33. doi: 10.1007/s00277-010-0968-3
- Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40(1):104–11. doi: 10.1097/CCM.0b013e31822e9d66
- Pequeño-Luévano M, Villarreal-Martínez L, Jaime-Pérez JC, Gómez-de-León A, Cantú-Rodríguez OG, González-Llano O, et al. Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases. Hematology. 2013;18(4):233–6. doi: 10.1179/1607845412Y.0000000073
- Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746–53. doi: 10.1182/blood-2011-03-341131
- Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013;11(3):481–90. doi: 10.1111/jth.12114
- McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201–8. doi: 10.1111/j.1538-7836.2010.03818.x
- Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012;119(16):3691–7. doi: 10.1182/blood-2011-06-363556
- Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329–34. doi: 10.1111/j.1600-0609.2010.01486.x
- Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Di Bona E, Fattizzo B, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546–51. doi: 10.1111/ejh.12199
- Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93(6):930–3. doi: 10.3324/haematol.12206
- Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, Jaime-Pérez JC, Ceballos-López AA, Ruiz-Argüelles GJ, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494–500. doi: 10.1111/ejh.12102
- Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116(23):4783–5. doi: 10.1182/blood-2010-06-291831
- Benjamin M, Terrell DR, Vesely SK, Voskuhl GW, Dezube BJ, Kremer Hovinga JA, et al. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009;48(8):1129–37.
- Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, et al. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura – favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol. 2011;153(4):515–9. doi: 10.1111/j.1365-2141.2011.08636.x
- Hie M, Gay J, Galicier L, Provot F, Presne C, Poullin P, et al. Preemtive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood. 2014;124(2):204. doi: 10.1182/blood-2014-01-550244
- Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015;125(10):1526–31. doi: 10.1182/blood-2014-10-559211